P&G Could Be Last Suitor Standing For Pfizer's Consumer Health Business
Executive Summary
A spin-off still is an option for Pfizer, as is continuing to operate the unit as it currently does. But P&G's apparent interest and dearth of other OTC business buyers changes the outlook for both companies.
You may also be interested in...
European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati
Bristol-Myers Squibb weighs selling its UPSA French OTC business, conducting a strategic review to assess its growth potential. Milan-based Recordati, says it plans to grow its OTC business; the firm sold a 51.8% stake owned by the Recordati family to a consortium of private equity funds for $3.56bn.
European OTC Shifts: BMS Eyes Selling French Business, Private Equity Controls Italy's Recordati
Bristol-Myers Squibb weighs selling its UPSA French OTC business, conducting a strategic review to assess its growth potential. Milan-based Recordati, says it plans to grow its OTC business; the firm sold a 51.8% stake owned by the Recordati family to a consortium of private equity funds for $3.56bn.
P&G Chooses Merck's Consumer Health Business In $4.2bn Deal
The global health, personal and household care marketer's agreement with the German firm that will bring under its roof nutritional products including Cebion vitamin C, Neurobion B complex vitamins, Femibion folic acid, Ominibionta 3 All Day Energy and Sangobion iron supplements.